By combining sub-picomolar sensitivity and unique molecular specificity, PET permits the investigation of several molecular targets. Researchers are now able to visualize and quantify molecular markers in the brain, including, but not limited to, pre- and post-synaptic neurotransmitter receptors, phosphodiesterases, neuroinflammation and proteins involved with the reuptake of several neurotransmitters.
Similar to PET imaging, single photon emission tomography (SPECT) also uses several radiotracers for in vivo assessment of brain function. SPECT imaging is generally less expensive and more widely available than PET imaging, making it a high desirable technique to explore brain functionality by measuring molecular markers in the brain. Essentially, PET and SPECT imaging enables investigators to explore the pathophysiology of a variety of CNS diseases, to not only improve understanding, but encourage the development of cutting-edge biomarkers and future disease-modifying therapies. By employing PET or SPECT imaging in early clinical development, drug distribution, target interaction and downstream pharmacology of novel drugs can be determined. This information plays a key role in providing dosing information for proof-of-concept studies, particularly by reducing both cost and time in early stage development.
Sitilop has robust operational knowledge and experience to conduct single- and multi-center clinical imaging studies, with expertise in modalities such as MR, SPECT and PET. Our researchers are well-equipped to support clients throughout the drug development pipeline, from study start-up to final delivery of the imaging outcomes, our imaging specialists have the skills and knowledge to manage and support imaging centers and clinical sites, ensuring all data is acquired and analyzed to the highest standard.
Molecular and functional imaging are unprecedented in their capacity to deliver key information on drug penetration, drug interaction with its molecular target and drug-induced modification of its target’s activity, particularly in the translational phase between late pre-clinical and early clinical phases. Given the non-invasive nature of neuroimaging, they can be employed in small, well-defined populations to provide crucial objective and reproducible results that enable Go-No-Go decisions to be made.
Sitilop combines innovative methodological expertise with clinical and biological knowledge, making Sitilop unique in its ability to yield optimal imaging support across all phases of drug development. Sitilop has unparalleled knowledge and experience in designing, conducting, analyzing and interpreting imaging studies, thus deliver outcome measures that permit critical decisions to be made.
Sitilop comprises of several experts who are proficient in carrying out multi-modality clinical imaging, including SPECT, PET and MRI, as well as their respective analyses using cutting-edge methodology and software. Our team has expertise in quantifying clinical amyloid PET scans using state-of-the-art techniques, as well as excellent proficiencies in interpreting DaTSCANs – both visually and semi-quantitively. Our researchers are competent in performing single- or multi-site clinical imaging research across all stages of the drug development pipeline (phases I-IV).
Clinical Trials and Research
Our vision is to drive healthcare forward, and accelerate this progress with our unique insights, and with our ability to reimagine and reinvent. Our team is constantly striving to innovate and find novel solutions to provide state-of-the-art services, in all aspects of clinical research, ranging from clinical activities, to the establishment of research protocols, regulatory and ethics submission, data analysis, using innovative and novel methodological approaches, and preparing materials for publication.